Cyclosporine-Induced neurotoxicity during treatment of Crohn's disease: lack of correlation with previously reported risk factors.
A 13-yr-old boy with severe Crohn's disease was admitted with persistent hematochezia requiring transfusion. Cyclosporine A was begun on hospital day 22 because of continued diarrhea and rectal bleeding despite high doses of i.v. corticosteroids. Six days into cyclosporine therapy, the patient developed multiple episodes of generalized tonic-clonic seizures accompanied with magnetic resonance imaging findings typical, although not pathognomonic, of cyclosporine A central nervous system neurotoxicity. Further investigations demonstrated that severe cyclosporine neurotoxicity may occur in the absence of previously reported clinical risk factors. Experience from the pediatric and adult GI transplant and neurological literature is discussed.
Rosencrantz
R
R
Department of Pediatrics, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10467-2490, USA.
Moon
A
A
Raynes
H
H
Spivak
W
W
D000293:Adolescent; D003424:Crohn Disease / Q000188:drug therapy*; D016572:Cyclosporine / Q000009:adverse effects*; D006801:Humans; D008297:Male; D020258:Neurotoxicity Syndromes / Q000209:etiology*; D012307:Risk Factors
D016572:Cyclosporine